246848-58-8

Basic information

• Product Name: 2-(2-Chlorophenyl)-1,2-dihydro-5-phenyl-3H-1,2,4-triazol-3-one
• Synonyms: 2-(2-Chlorophenyl)-1,2-dihydro-5-phenyl-3H-1,2,4-triazol-3-one;2-(2-Chlorophenyl)-1,2-dihydro-5-phenyl-3H-1,2,4-
• CAS NO: 246848-58-8
• Molecular Formula: C₁₄H₁₀ClN₃O
• Molecular Weight: 271.7017
• Mol File: 246848-58-8.mol

Chemical Properties

• Boiling Point: 386.506°C at 760 mmHg
• Flash Point: 187.552°C
• Appearance: /
• Density: 1.363g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.676
• PKA: 6.63±0.20(Predicted)
• CAS DataBase Reference: 2-(2-Chlorophenyl)-1,2-dihydro-5-phenyl-3H-1,2,4-triazol-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-Chlorophenyl)-1,2-dihydro-5-phenyl-3H-1,2,4-triazol-3-one(246848-58-8)
• EPA Substance Registry System: 2-(2-Chlorophenyl)-1,2-dihydro-5-phenyl-3H-1,2,4-triazol-3-one(246848-58-8)

Safety Data

• Hazardous Substances Data: 246848-58-8(Hazardous Substances Data)

Usage

Chemical class

Triazolone derivatives

Physical appearance

White to off-white crystalline powder

Molecular weight

292.73 g/mol

Pharmacological properties

Anxiolytic and sedative-hypnotic effects

Potential therapeutic uses

Treating anxiety and sleep disorders

Ongoing research

Exploring pharmacological effects and safety profile

Precautions

Potential for adverse health effects if not properly managed

InChI:InChI=1/C14H10ClN3O/c15-11-8-4-5-9-12(11)18-14(19)16-13(17-18)10-6-2-1-3-7-10/h1-9H,(H,16,17,19)

Upstream product

• 41052-75-9 o-chlorophenylhydrazine hydrochloride 
• 917-61-3 sodium isocyanate 
• 26946-54-3 N'-(2-chlorophenyl)benzohydrazonoyl chloride 
• 65-85-0 benzoic acid 
• 108-73-6 3,5-dihydroxyphenol 
• 79984-70-6 N’-(2-chlorophenyl)benzohydrazide 

Relevant articles and documents

Synthesis of 3 H-1,2,4-Triazol-3-ones via NiCl2-Promoted Cascade Annulation of Hydrazonoyl Chlorides and Sodium Cyanate

A nickel-promoted cascade annulation reaction for the facile synthesis of 3H-1,2,4-triazol-3-ones from readily available hydrazonoyl chlorides and sodium cyanate has been developed. The transformation occurs through a cascade nickel-promoted intermolecular nucleophilic addition-elimination process, intramolecular nucleophilic addition, and a hydrogen-transfer sequence. The method has been successfully applied for the construction of the core skeleton of the angiotensin II antagonist.

Palladium-Catalyzed cascade carbonylative synthesis of 1,2,4-triazol-3-ones from hydrazonoyl chlorides and NaN3

A palladium-catalyzed three-component carbonylative reaction for the synthesis of 3H-1,2,4-triazol-3-ones from hydrazonoyl chlorides and NaN3 has been achieved. The reaction presumably proceeds through a cascade carbonylation, acyl azide format

Green preparation method of 1,2,4-triazol-3-one compound

The invention discloses a green preparation method of a 1,2,4-triazol-3-one compound. The green preparation method comprises the following steps: adding a nickel accelerant, triethylamine, chlorohydrazone and sodium cyanate into an organic solvent, conduc

Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones

A method for treating a neurodegenerative disease or cerebral ischemia arising from conditions selected from the group consisting of Status epilepticus, hypoglycaemia, hypoxia, anoxia, brain trauma, brain oedema, amyotropic lateral sclerosis, Huntington's disease, Alzheimer's disease, hypotonia, cardiac infarction, brain pressure (elevated intracranial pressure), ischaemic and haemorrhagic stroke, global cerebral ischaemia with heart stoppage, diabetic polyneuropathy, tinnitus, perinatal asphyxia, psychosis, schizophrenia, depression, and Parkinson's disease, the method of treatment comprising administering to a host in need of such treatment a therapeutic amount of a compound of formula (I) wherein R1, R2, R3, R4, R5, R6, and R7 are as defined herein, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions containing a compound of formula (I).